Friday, May 27th, 2022
THEME:
Prevention and Treatment of Substance Use Disorders:
Progress and Prospects for Psychedelic Science
Master of Ceremonies: Dr. Dominique Morisano
8:15 am – 9:00 am
Conference Opening
- Land acknowledgement: Dr. Brian Rush, CAMH and Dalla Lana School of Public Health, University of Toronto
- Opening Prayer and Song from Walter Lindstone, Batchewana First Nation Anishinaabe and CAMH (Shkaabe Makwa)
- Brief Welcome from Planning Committee (Drs. Dominique Morisano, Brian Rush, Monnica Williams, Doris Payer, Sukhpreet Klaire, Thomas Babor, and Mary Bartram)
- Welcome from host institutions (CAMH, CCSA, MHCC)
- Remarks by Nathaniel Erskine-Smith, Member of Parliament, Beaches-East York
- Day 1 Master of Ceremonies: Dr. Dominique Morisano
9:00 am – 9:50 am
Keynote Presentation #1
Historical and recent advances in psychedelic science, neuroscience and clinical contributions to substance use and addictions
- Dr David Nutt; Imperial College London, Awakn Life Sciences
- Discussant: Dr Sukhpreet Klaire, University of British Columbia
9:50 am – 10:00 am
Keynote Presentation Q and A
10:00 am – 10:30 am
Break
10:30 am – 11:45 am
Peer-Reviewed Paper presentations
Peer-Reviewed Paper presentations focused on neuroscience/clinical findings in substance use/addictions (4 of 15 minutes)
Details
ID-25
Abstract
The impact of ineffective placebo control in microdosing trials
Authors
- Dr. Balazs Szigeti, Imperial College London;1
- Dr. Robin Carhart-Harris, University of California, San Francisco;
- Dr. David Erritzoe, Imperial College London
ID-8
Abstract
MDMA Therapy for the Treatment of Alcohol Use Disorder: The Results of the World’s First Study – And Plans for Ongoing Further Research.
Authors
- Dr. Ben Sessa, Imperial College London
ID-11
Abstract
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
Authors
- Dr. Elizabeth Nielson, Fluence
ID-65
Abstract
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
Authors
- Peter Bedford, Centre for Addiction and Mental Health;
- Daniel Hauke, University of Basel;
- Zheng Wang, Centre for Addiction and Mental Health;
- Dr. Volker Roth, University of Basel;
- Monika Nagy-Huber, University of Basel;
- Friederike Holze, University of Basel;
- Laura Ley, Departement Biomedizin, University of Basel;
- Dr. Patrick Vizeli, Departement Biomedizin, University of Basel;
- Dr. Matthias Liechti, University of Basel;
- Dr. Stefan Borgward, University of Basel;
- Dr. Felix Müller, University Psychiatric Clinics Basel;
- Dr. Andreea Diaconescu, Centre for Addiction and Mental Health
*The presenting author is underlined.
11:45 am – 12:45 pm
Lunch (onsite, included)
12:45 pm – 1:35 pm
Keynote Presentation #2
Traditional medicine, culture and psychedelic science: Healing for substance use and addictions
- Dr. Anja Loizaga-Velder, Nierika Institute for Intercultural Medicine
- Discussant: Dr. Olivia Marcus, New York University
1:35 pm – 1:45 pm
Keynote Presentation Q and A
1:45 pm – 3:15 pm
Peer-Reviewed Paper presentations
Peer-Reviewed Paper Presentations focused on traditional approaches to substance use/addictions (5 of 15 minutes)
Details
ID-47
Abstract
Naturalistic Psychedelic use Among Indigenous Peoples to Alleviate Racial Trauma
Authors
- Sara de la Salle, University of Ottawa;
- Sophia Gran-Ruaz, University of Ottawa;
- Dr. Dawn Davis, NativeSci;
- Dr. Monnica Williams, University of Ottawa;
- Dr. Alan Davis, Ohio State University
ID-22
Abstract
Integrating Anthropological Knowledge into Psychedelic Spiritual Care: How Indigenous
Wisdom and Ayahuasca Religions can inform Best Practice
Authors
- Dr. Marc Blainey, Homewood Health Centre
ID-114
Abstract
Preliminary results from the Ayahuasca Treatment Outcome Project (ATOP): Takiwasi Center Peru.
Authors
- Dr. Brian Rush, Centre for Addiction and Mental Health, University of Toronto
- Dr. Olivia Marcus, New York University
- Sara Garcia, Takiwasi Centre, Peru
- Dr. Anja Loizaga-Velder, Nierika Institute, National Autonomous University of Mexico, Mexico
- Gabriel Loewinger, Harvard University School of Public Health
- Ariane Spitalier, Autonomous University of Barcelona, Spain
- Dr. Fernando Mendive, Takiwasi Centre, Peru
ID-28
Abstract
Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being
Authors
- Maggie Kiraga;
- Dr. Natasha Mason, Maastricht University;
- Dr. Malin Uthaug, Maastricht University;
- Dr. Kim van Oorsouw, Maastricht University;
- Dr. Stefan Toennes, University of Frankfurt;
- Dr. Johannes Ramaekers, Maastricht University;
- Dr. Kim Kuypers, Maastricht University
3:15 pm – 3:45 pm
Break
3:45 pm – 5:15 pm
Peer-Reviewed Paper presentations
Peer-Reviewed Paper Presentations focused on policy, public health, and regulatory issues in substance use and addictions (5 of 15 minutes)
Details
ID-46
Abstract
Psychedelics for addiction treatment: enabling access and protecting innovation and opportunity through preserving the public domain
Authors
- Shahin Shams, Porta Sophia;
- Dr Sisi Li, Porta Sophia;
- Amanda Pratt, Holtz Center for Science and Technology Studies;
- Dr. David Casimir, Casimir Jones S.C.;
- Dr. Thomas Isenbarger, Casimir Jones S.C.
ID-50
Abstract
From Policy to Practice, Practice to Policy (P2P): An Interdisciplinary and Practice Based Approach to Ketamine Assisted Therapy Policy Development in Canada
Authors
- Dr. Anthony Barale, The Ketamine Assisted Therapy Association of Canada;
- Dr. Ian Mitchell, Royal Inland Hospital;
- Dr. Joel Kailia, The Ketamine Assisted Therapy Association of Canada;
- Madison Nobbs, Ketamine Assisted Therapy Association of Canada;
- Dr. Neil Hanon, Ketamine Assisted Therapy Association of Canada;
- Dr. Sukh Dhiman, The Ketamine Assisted Therapy Association of Canada
ID-118
Abstract
The future of psychedelic therapies in health system stewardship
Authors
- Dr. Kenneth Tupper, University of British Columbia
ID-5
Abstract
The Canadian Psychedelic Survey; A Cross-Sectional Survey of Psychedelic Use in Canada
Authors
- Dr. Philippe Lucas, Sabi Mind
5:15 pm – 5:30 pm
Break
5:30 pm - 6:30 pm
Evening Panel
Policy, public health, and regulatory issues: Setting the research agenda for psychedelic-assisted therapies for substance use disorders
What are the steps for developing new treatment pathways for substance use disorders with psychedelic-assisted therapies including key research questions, regulatory issues, risk assessment, potential concerns or benefits, etc.
- Dr. Ken Tupper, University of British Columbia, Canada
- Ifetayo Harvey, POC Psychedelic Collective, USA
- Dr. Gady Zabicky Sirot, Mexican CONADIC National Council on Addictions, Mexico
- Dr. Ben Sessa, Imperial College London and Awakn Life Sciences, UK
- Dr. Anja Loizaga-Velder, Nierika Institute for Intercultural Medicine, Mexico
- Moderator: Dr. Dominique Morisano, University of Toronto/University of Ottawa/CAMH
8:00 pm – 9:30 pm
Networking Social Event
Saturday, May 28th, 2022
THEME:
Prevention and Treatment of Mental Health Disorders:
Part I: Neuroscience/ Clinical Applications; Traditional Medicine/Cultural Considerations
Master of Ceremonies: Mary Sanders
8:45 am – 9:00 am
Opening Remarks and Working Documentary Sneak Peak: Transcendence produced by A Colorful World and directed by Esteban Serrano
- Presented by Victor Cabral, Fluence and American Psychedelic Practitioners Association
- https://www.pictureacolorfulworld.com/
9:00 am - 9:50 am
Keynote Presentation #3
Psychedelics and Racial Justice
- Dr. Monnica Williams, School of Psychology, University of Ottawa
- Discussant: Victor Cabral, Fluence and American Psychedelic Practitioners Association
9:50 am – 10:00 am
Keynote Presentation Q and A
10:00 am – 10:45 am
Poster Viewing and Refreshment Break
Details
ID | Poster Title | Presenter |
124 | A Matter of Context: A Comparative Study of Generational Media and its Impact on Psychedelic Policy and Regulations | Michael Kydd |
86 | A vision for psychedelic research in Canada | Scott Bernstein |
19 | Analysis of the brain’s energy landscape dynamics during psilocybin and escitalopram treatment for depression | Parker Singleton |
LB204 | Ayahuasca Awakening A Guide to Self-Discovery Self-Mastery and Self-Care | Jessica Rochester |
79 | Behavioural Investigations of Psilocybin in Animals, A Scoping Review | Kat Dobson |
110 | Creating an Intercollegiate Psychedelics Network: Student Empowerment with a Global Reach | Joel Lopez |
82 | Does psilocybin change synaptic density in the brains of patients with mild cognitive impairment? A double-blind placebo-controlled study design | Jianmeng Song |
54 | Experiences of Psychedelic Use Among Individuals with Psychotic Symptoms | Jade Gallo |
32 | Functional connectivity during a personalized trauma audio task is altered after MDMA-assisted psychotherapy in PTSD patients and correlates with recovery | Parker Singleton |
LB207 | Ketamine and psilocybin differentially impact top-down predictions during the mismatch negativity: An EEG Study | Shona Allohverdi |
LB203 | Looking through the doors of perception: the past, present and future of psychedelics to treat addiction | Rayyan Zafar |
80 | Mushrooms, madness, media: a content analysis of Canadian news media and how it frames the relationship between psilocybin and violence. | David Kryszajtys |
9 | Neural correlates of anti-suiciDal rEsponse to kEtamine in treatment resistant biPolar dePression (DEEPP-Study). Opel Label Pilot Clinical Trial | Yuliya Knyahnytska |
115 | Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: A Protocol for An Emotional-Processing fMRI Pilot Study | Joshua Rosenblat |
14 | Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics | Lily Aleksandrova |
68 | Patterns of Hallucinogen Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada between 2006 and 2020 | Judy Castañeda |
67 | Pharmacological and Pharmacokinetic Profile of CYB003, a Novel, Orally Active Analog of Psilocybin | Geoff Varty |
99 | Point of Departure: Training & the Psychedelic Therapeutic Paradigm | Anne Vallely |
121 | Preliminary Evidence that a Reduction in Racial Trauma Symptoms Mediates the Association between Acute Psychedelic Effects and Reduced Alcohol Use among People of Color in the United States and Canada | Angela Haeny |
117 | Psilocybin’s mechanism of action in the treatment of depression | Brandon Chai |
21 | Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian Setting | Elena Argento |
95 | Psychedelic use, mental health, and suicidality in Canadian university students | Julia Pei |
89 | Research Abuses Against People of Colour in Early Psychedelic Research and Implications for Psychedelic Research, Therapy, and Policy | Dana Strauss |
55 | Serotonergic Psychedelic Drugs Dynamically Reconfigure Brain Network Organization | Manesh Girn |
126 | The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Investigation of Hallucinogenic Substances | Theresa Carbonaro |
36 | The effect of psilocybin therapy for depression on low-frequency brain activity in response to music | Natalie Ertl |
43 | The effects of psilocybin-induced glucocorticoid release on post-acute and delayed anxiolysis in mice | CODY WENTHUR |
61 | The use of psychedelic substances for smoking cessation: A systematic review | Arina Bogdan |
49 | Therapeutic Intent and Caregiver Communication in Psychedelic Medicine | Lucas Standing |
90 | Will Psychedelic-Assisted Therapies Benefit from COVID-19 Pharmaceutical Regulatory Modernization? The Future of ‘Alternative’ Therapies in Canada | Agnieszka Doll |
10:45 am – 12:15 pm
Peer-Reviewed Paper presentations
Peer-Reviewed Paper presentations focused on neuroscience/clinical findings (5 of 15 minutes)
Details
ID-81
Abstract
Ketamine-Assisted and Psilocybin-Assisted Therapies, delivered within a Community of Practice Framework: Operations and Outcomes of the Roots to Thrive model
Authors
- Shannon Dames, Vancouver Island University;
- Pamela Kryskow, Vancouver Island University
ID-78
Abstract
The Effects of Psilocybin on Cognitive and Neural Flexibility: The Limits of Excessive Flexing
Authors
- Dr. Manoj Doss, Johns Hopkins University School of Medicine
ID-93
Abstract
Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators
Authors
- Joseph Rootman, UBC Okanagan;
- Dr. Pamela Kryskow, Vancouver Island University;
- Dr. Maggie Kiraga;
- Paul Stamets;
- Kalin Harvey, Quantified Citizen;
- Eesmyal Santos-Brault, Quantified Citizen;
- Dr. Kim Kuypers, Maastricht University;
- Dr. Zach Walsh, University of British Columbia – Okanagan
ID-106
Abstract
A False Renaissance: The story of the first mainstream psychedelic
Authors
- Dr. Elias Dakwar, Columbia University
ID-75
Abstract
Trial of Psilocybin versus Escitalopram for Depression; 6 months follow-up data
Authors
- Dr. David Erritzoe, Imperial College London;
- Dr. Rosalind Watts, Twelve Trees Integration Ltd;
- Bruna Giribaldi, Imperial College London;
- Balazs Szigeti, Imperial College London;
- Dr. Fernando Rosas, Imperial College London;
- Dr. David Nutt, Imperial College London;
- Dr. Robin Carhart-Harris, University of California, San Francisco
12:15 pm – 1:15 pm
Lunch (onsite, included)
1:15 pm – 2:45 pm
Peer-Reviewed Paper presentations
Peer-Reviewed Paper Presentations focused on Traditional approaches (5 of 15 minutes)
Details
ID-51
Abstract
Revolution or an endless cycle? The epistemic and ethical concerns of psychedelic psychiatry
Authors
- Dr. Olivia Marcus, New York University
ID-63
Abstract
Psychedelic Medicine and Muslim Communities: From Sufism to the Modern Era
Authors
- Dr. Manzarsadat Zareashkezari, University of Ottawa
ID-29
Abstract
Exploring experiences and perceptions around purging during Ayahuasca rituals: a qualitative study at a drug rehabilitation center in Peru
Authors
- Svĕt Lustig Vijay, London School of Tropical Hygiene and Medicine;
- Fabio Friso, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines;
- Dr. Magdalena Harris, Department of Public Health, Environments and Society, London School of Tropical Hygiene and Medicine;
- Dr. Matteo Politi, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines
ID-96
Abstract
Culturally-Safe PsychedelicAssisted Psychotherapy: A Foundation for Training Programs
Authors
- Tatiana Sanchez, University of British Columbia – Okanagan;
- Sarah Daniels, University of British Columbia – Okanagan;
- Michelle St. Pierre, The University of British Columbia;
- Joseph Rootman, UBC Okanagan;
- Christopher Nelson, University of British Columbia – Okanagan;
- Dr. Zach Walsh, University of British Columbia – Okanagan
2:45 pm – 3:15 pm
Refreshment Break
3:15 pm – 4:35 pm
Keynote Presentation #4
Spirit in Science—Traditional and Indigenous Perspectives on Healing Trauma with Psychedelic Plant Medicines
- Dr. Joseph Tafur, Modern Spirit and Ocotillo Center for Integrative Medicine, author of Fellowship of the River;
- Susan Beaulieu, Red Lake Nation Anishinaabe and the University of Minnesota
- Chief Derek Cook, Bloodvein First Nation (Manitoba, Canada)
- Rainbow Lopez, Tohono O’odham Nation
- Christine Diindiisi McCleave, Turtle Mountain Anishinaabe and University of Alaska Fairbanks
4:35 pm – 4:45 pm
Keynote Presentation Q and A
4:45 pm – 5:45 pm
Late Breaking Research Presentations (all topics) (3 x 15 minutes)
All topics (3 of 15 minutes)
Details
Traditional medicine and cultural considerations
ID-LB213
What Ayahuasca and Shipibo Plant Medicine Taught Me About Healing the Roots of Racism
Authors:
- Chaikuni Witan, NIhue Ras Centro Espirtual
Neuroscience and clinical applications
ID-LB202
Ibogaine and Acute Opioid Detoxification
Authors:
- Dr. Alberto Sola, Clear Sky Recovery Cancun
- Hirpal Hundial, Universal Ibogaine
Neuroscience and clinical applications
ID-LB209
Watch Now
Treatment response in psilocybin-assisted therapy is predicted by baseline neuroticism and mediated by mystical experience and emotional breakthrough
Authors:
- Brandon Weiss, Imperial College
- David Erritzoe, Imperial College London
- Robin Carhart-Harris, University of California, San Francisco
5:45 pm - 6:00 pm
7:30 pm - 9:00 pm
Public Event
Psychedelic-Assisted Therapy - Facts & Fiction featuring some of the world’s top researchers in the field of psychedelic-assisted therapies and medicine
- Dr. David Nutt, Imperial College London
- Ifetayo Harvey, POC Psychedelic Collective
- Dr. Dawn Davis, Native Sci CEO
- Dr. Monnica Williams – School of Psychology, University of Ottawa
- Dr. Olivia Marcus – New York University
- Dr. Rick Doblin – MAPS
- Moderator: Dr. Brian Rush, CAMH/University of Toronto
Sunday, May 29th, 2022
THEME:
Prevention and Treatment of Mental Health Disorders:
Part II: Public Health, Policy, and Regulatory Considerations
Master of Ceremonies: Dr. Dominique Morisano
8:30 am – 8:45 am
Opening Remarks and Commentary on Challenges in Conducting Clinical Research with Schedule I Psychedelics: From the 1960s to the Present
- Dr Katherine Bonson, U.S. Food and Drug Administration (Virtual)
8:45 am – 9:25 am
Keynote Presentation #5
Ketamine-Assisted Psychotherapy in North America: A Review and Commentary
- Dr. Steven Rosonke, Rainfall Medicine
- Dr. Devon Christie, Numinus Wellness and UBC Family Medicine
- Discussant: Dr. Dominique Morisano
9:25 am – 9:45 am
Keynote Presentation Q and A
9:45 am – 10:30 am
Poster Viewing and Refreshment Break
Details
ID | Poster Title | Presenter |
LB206 | A New Path for Hope: Therapeutic Potential of 5-MeO-DMT – from Nature, to Synthesis, to Health Equity | Robert Kargbo |
16 | A Study Design for a Pragmatic, Open-Label, Phase 2 Study of Psilocybin-Research Intervention with Motivational Enhancement for Substance Use Disorders (PRIME-SUD)” | Lindsay Mackay |
119 | Accounting for the Clinical Efficacy of Psychedelic Therapies: How to Reconcile Mysticism and the Scientific Worldview? | Tuomas Pernu |
88 | Alcohol use, mental health outcomes, and psychedelic use: do mystical experiences matter? | Tashia Petker |
15 | Clinical applications of attachment theory in psychedelic-assisted therapy for substance use disorder | Aaron Cherniak |
LB210 | Computationally defined suicidality subtypes and their differential response to psilocybin vs ketamine therapy | Povilas Karvelis |
64 | Design and Rationale for an Open-Label Clinical Trial to Evaluate the Feasibility, Clinical Effects, and Safety of Psilocybin-Assisted Psychotherapy for Treatment- Body Dysmorphic Disorder and Treatment-Resistant Obsessive-Compulsive Disorder. | Nicole Ledwos |
113 | Development and Implementation of a Canadian Psilocybin-Assisted Therapy Training Program | Joshua Rosenblat |
77 | Entity Encounters on Psychedelics: An Active Inference Account of Spirits, Guides, and Invisible Presences | Jonas Mago |
34 | Examining the prevalence and impact of adverse life event re-experiencing during the ceremonial use of ayahuasca | Brandon Weiss |
92 | Examining the association between psychedelic use, mental health and the COVID-19 pandemic in young adults who use substances | Christopher Nelson |
39 | How the “we” helps heal the “me”: psychedelic peer supports and communities of care | Amy Bartlett |
7 | Intranasal Ketamine in ECT Non-responders with Treatment Resistant Depression. Open Label Pilot Clinical Trial | Yuliya Knyahnytska |
94 | Ketamine for the treatment of mental health and substance use disorders: a comprehensive systematic review | Shannon Golsof |
40 | L’induction photonique des états de transe : une alternative efficace et élégante aux substances psychoactives en général | Alexandre Quaranta |
102 | Low-Dose Psycholytic Therapy: A Neglected Approach? | Torsten Passie |
24 | MDMA-assisted therapy: exploratory data demonstrates potential for chronic pain | Devon Christie |
87 | Novel Therapies for First Responders and Military Veterans | Jonathan Hill |
74 | Personalized medicine and psychedelics | Olga Chernoloz |
73 | Psilocybin as a Treatment for Anorexia Nervosa: Study Protocol and 6-Month Feasibility Update | Hannah Douglass |
116 | Psilocybin-assisted psychotherapy for Post-traumatic Stress Disorder in Veterans: a protocol description | Rakesh Jetly |
LB212 | Psychedelic Report Index: A Standardized Tool For Indexing and Tracking Subjective Reports of Psychedelic Associated Experiences | Marcos Ibrahim |
72 | Randomized, double-blind, placebo-controlled study assessing the efficacy of microdosed psilocybin on reducing depression and/or anxiety levels in adults. | Olga Chernoloz |
111 | Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Mood Disorders | Joshua Rosenblat |
69 | Right-Wing Psychedelia: Political Pluripotency and Ideology on Drugs | Brian Pace |
66 | Safety and Efficacy of Serotonergic Psychedelic Drugs for the Treatment of Anxiety Disorders and Obsessive-Compulsive Disorder: A Systematic Review | Jamie Hujan |
42 | Psychedelic interventions to alleviate psychological suffering at the end of life: Protocol for a scoping review | Sarah Kratina |
18 | The Condor and the Eagle: Integrating South and North Indigenous traditions | Michael Chaiton-Murray |
112 | The efficacy and tolerability of psilocybin in participants with treatment-resistant depression: a phase 2, randomized feasibility study | Joshua Rosenblat |
127 | The Relationship between Classic Psychedelics and Suicidality: A Systematic Review | Nikhita Singhal |
56 | Therapeutic Uses of Psychedelics for Eating Disorders and Body Image Disorders: A Narrative Review | Justyne Rodas |
120 | TRIP protocol for treatment resistant depression. | Tatiana Zdyb |
10:30 am – 12:00pm
Peer-Reviewed Paper presentations
Peer-Reviewed Paper presentations focused on policy, public health, and regulatory issues (5 of 15 minutes)
Details
ID-98
Abstract
The Need for Psychedelic-Assisted
Therapy in the Black Community
and the Burdens of its Provision
Authors
- Dr. Sonya Faber, Bioville GmbH;
- Dr. Darron Smith, The University of Memphis (Virtual)
ID-100
Abstract
Entheogens and Psychedelics in
Canada, Proposal for a New Paradigm: A Call for a National Advisory Council
Authors
- Rev Dr. Jessica Rochester, Céu do Montreal;
- Dr. Anne Vallely, University of Ottawa;
- Dr. Monnica Williams, University of Ottawa;
- Dr. Paul Grof, Mood Disorders Centre of Ottawa;
- Kate Caldwell, Interaction Experience;
- Dr. Harvey Chang, Jewish General Hospital
ID-58
Abstract
Psychedelics and the Commercial Determinants of Health: An Ethics
Case Study Analysis of Psychedelic
Industry-Healthcare Relationships
Authors
- Dr. Daniel Buchman, Centre for Addiction and Mental Health
ID-76
Abstract
A grounded theory of online
community members’ self-reported
decision-making logic before their
first use of psychedelic self-treatment for depression and/or anxiety.
Authors
- David Kryszajtys, University of Toronto;
- Dr. Jacqueline Bender, University Health
Network; - Dr. Brian Rush, Centre for Addiction and Mental Health;
- Carol Strike, University of Toronto
ID-23
Abstract
From Research to Regulatory Negotiations to Reality
Authors
- Dr. Rick Doblin, MAPS
12:00 pm – 1:00 pm
Lunch (onsite, included)
1:00 pm - 2:30 pm
Panel Presentation
World Regulatory and Policy Discussion: A Pathway Forward
- Dr. Javier Muniz, U.S. Food and Drug Administration;
- Dr. Jorge Julio Gonzalez Olvera, Director of Attention Models in Mental Health at the Secretariat of the Mexican Board of Mental Health;
- Dr. Florence Butlen-Ducuing, European Medicines Agency (Virtual);
- Drs. Jennifer Pelley and Daniel Keene, Health Canada (Virtual);
- Moderator: Dr. Doris Payer, Canadian Centre on Substance Use and Addiction
2:30 pm - 3:15 pm
Closing Plenary
Psychedelics in mental health and addiction treatment
- Dr. Matthew Johnson, Center for Psychedelic and Consciousness Research, Johns Hopkins University
3:15 pm – 3:30 pm
Closing Plenary Q and A
3:30 pm – 4:00 pm
Closing Prayer and Acknowledgements
- Prayer by Elder Clayton Shirt, Plains Cree/Anishinaabe
- Closing Remarks and Acknowledgements by R2R2022 Co-Founders Drs. Dominique Morisano (CAMH/University of Toronto/University of Ottawa) and Brian Rush (CAMH/University of Toronto)
Stay up to date with global research efforts.
Webinar series is co-hosted by the Evidence Exchange Network (EENet).
